increased hospitalization and mortality from hyperkalemia, whereas HF mortality was not reduced. 7 Concerns have been raised that MRAs may not be associated with net benefits in clinical practice. 8 Therefore, the objective was to test the hypothesis that spironolactone is associated with reduced mortality in a broad unselected contemporary HF population and specifically in NYHA I-II.
Methods

Study Protocol
The Swedish Heart Failure Registry has been previously described. 9, 10 Inclusion criteria were clinician-judged HF. Eighty variables were recorded at discharge from hospital or clinic visit and entered into an electronic database managed by the Uppsala Clinical Research Center (Uppsala, Sweden). The database is run against the Swedish death registry monthly. The protocol, registration form, and annual report are available at www.rikssvikt.se. Establishment of the registry and registration and analysis of the data were approved by a multisite ethics committee. Individual patient consent was not required or obtained, but patients were informed of entry into national registries and were allowed to opt out. The registry and this study conform to the Declaration of Helsinki.
The registry does not specify MRA agent (spironolactone or eplerenone), but according to the Swedish Board of National Health and Welfare, >98% of MRAs prescribed in Sweden are spironolactone (data extracted September 9, 2010) . Therefore, we consider our study applicable to spironolactone and refer to spironolactone throughout.
Between May 11, 2000 , and April 22, 2012, there were 73 471 registrations from 66 of 77 hospitals and 97 of 1011 primary care outpatient clinics in Sweden. Of 48 020 unique patients, 7301 had EF missing, 17 389 had EF ≥40%, 139 had spironolactone missing, 4247 had NYHA missing, 84 were lost to follow-up, 7 had negative follow-up (registered after running against the death registry), and 1 had age missing, leaving 18 852 patients with NYHA I-IV and EF <40% included for this study.
Statistical Analysis
To avoid bias attributable to missing baseline variables, multiple imputation (n=10) was performed for variables with missing data, using predictive mean matching. 11 Subsequent analyses, except for descriptive statistics (Table 1) , were performed on imputed data (mean of the 10 imputed data sets). To adjust for selection bias, propensity scores 12, 13 for each patient were estimated with logistic regression, with spironolactone "yes" as the outcome. Forty-one baseline variables were chosen for imputation and derivation of propensity scores, based on clinical relevance and ability to correct for differences between spironolactone "yes" versus "no" groups.
Survival was charted with the Kaplan-Meier method and compared with the log-rank test. Univariable and multivariable Cox regressions were performed, with adjustment for propensity score as a continuous covariate. To avoid nonlinear hazard, continuous covariates were entered into the model as restricted cubic splines. Violations to the proportional hazards assumption were ruled out by scaled Schoenfeld residuals. Interactions between spironolactone and baseline variables were estimated by Cox regression. Continuous variables were analyzed as continuous when assessing interactions but dichotomized at clinically relevant cutoffs based on RALES, EPHESUS, and EMPHASIS-HF when displayed in a Forest plot. We also created and analyzed a cohort of treated versus untreated patients matched 1:1 based on difference in age ≤0.1 mutual SDs and in propensity score ≤0.01 mutual SDs. This yielded 5280 patients in each group with a difference of ≤1 years of age and ≤0.0029 U of propensity score.
Propensity scores were calculated from known and measured potential confounders (n=41 in our study). However, unmeasured confounders may affect the results if they are unrelated to or not fully accounted for by measured confounders and affect the decision to prescribe spironolactone and are associated with mortality independent of spironolactone. Therefore, we quantified the effects of hypothetical unmeasured confounders 10, 14, 15 (online-only Data Supplement).
To minimize potential confounding attributable to the multiple imputation, we also performed sensitivity analyses, including only patients with none of the 41 variables missing and with/without potassium and with/without patients with potassium missing (onlineonly Data Supplement).
In RALES, EPHESUS, and EMPHASIS-HF, the estimated annual mortality ranged 7% to 17% in treatment and 9% to 23% in placebo arms. Conservatively, we assumed a 1-year mortality of 13% versus 15% in spironolactone "yes" versus "no." To test the null hypothesis that there is no difference in mortality between the 2 groups, ≥4721 patients would be needed in the smallest group for a power of 80% and a 2-sided significance level of 0.05.
Statistics was performed in R version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria).
Subgroup Analyses
To address the hypothesis that spironolactone is associated with reduced mortality specifically in NYHA I-II, we assessed the interaction between treatment and NYHA class and also performed subgroup analyses in NYHA I-II separately, and for completeness, in NYHA III-IV separately. For these, multiple imputations remained the same as for the overall study. Because the determinants of spironolactone treatment may vary in NYHA I-II (potentially more likely with NYHA II and other markers of more severe HF) versus NYHA III-IV (potentially more likely with NYHA III and other markers potentially associated with, eg, better renal function), new propensity scores were derived within each subgroup. Within each subgroup, Cox regressions were then performed as for the overall cohort: univariable, with adjustment for propensity score, and in a matched cohort.
Results
Baseline characteristics and probability values before and after adjustment for propensity scores are shown in Table 1 . Of 18 852 patients, 6551 (35%; mean±SD age 70±12 years; 28% women) received spironolactone and 12 301 (65%; 72±12 years; 28% women) did not. In unadjusted analysis, patients receiving spironolactone were younger with better renal function and received more HF drug and device therapy, but were otherwise less healthy. Spironolactone use was slightly more common in NYHA III-IV versus I-II, and within these subgroups, slightly more common in NYHA II versus I and in NYHA III versus IV. However, after adjustment for propensity scores, there were no differences between the groups in any variables. Figure 1 shows survival. One-year survival was 83% (95% confidence interval [CI], 82%-84%) for treated and 84% (95% CI, 83%-84%) for untreated patients, respectively, and 5-year survival was 50% (95% CI, 48%-51%) and 54% (95% CI, 53%-55%), respectively (log rank P<0.001). Table 2 shows hazard ratio (HRs) for all-cause mortality in treated versus untreated patients; the multivariable HR after adjustment for propensity scores was 1.05 (95% CI, 1.00-1.1; P=0.054). The matched HR was 1.10 (95% CI, 1.01-1.19; P=0.020). Figure 2 shows HRs for spironolactone adjusted for propensity scores, for listed baseline variables and for the interaction between spironolactone and the baseline variable. Clinically important and statistically significant interactions where spironolactone were associated with increased mortality were for age < median (73), NYHA I-II, EF 30% to 39%, and creatinine clearance >50 mL/min. There were no interactions, where spironolactone was associated with reduced mortality. Figure 3A and 3B shows survival in the NYHA I-II and III-IV subgroups. In NYHA I-II, 1-year survival was 90% (95% CI, 89%-91%) for treated and 91% (95% CI, 90%-92%) for untreated patients, respectively, and 5-year survival was 63% (95% CI, 61%-65%) and 67% (95% CI, 65%-68%), respectively (log rank P=0.008). In NYHA III-IV 1-year survival was 77% (95% CI, 75%-78%) for treated and 74% (95% CI, 73%-75%) for untreated patients, respectively, and 5-year survival was 39% (95% CI, 37%-41%) and 38% (95% CI, 36%-39%), respectively (log rank P=0.029). Table 2 shows HRs for all-cause mortality in treated versus untreated patients in the NYHA I-II and III-IV subgroups. In NYHA I-II, the multivariable HR after adjustment for propensity scores was 1.11 (95% CI, 1.02-1.21; P=0.019). The matched HR was 1.06 (95% CI, 0.93-1.21; P=0.372). In NYHA III-IV, the multivariable HR after adjustment for propensity scores was 1.05 (95% CI, 0.99-1.12; P=0.108). The matched HR was 1.08 (95% CI, 0.99-1.18; P=0.088).
Residual confounding analyses (online-only Data Supplement) suggest that for the results to change, ie, for spironolactone to be significantly associated with reduced mortality, potential confounders would have to be as follows: a binary confounder with a HR of 2.0 or more present in 20% (absolute) or more treated patients; a continuous confounder with a HR of 1.2 to 1.5 per unit or more being 0.3 to 0.6 U or more higher in treated patients. Sensitivity analyses for missing data were consistent with the overall analysis (online-only Data Supplement).
Discussion
In this large unselected general HF population with EF <40% and NYHA I-IV, and of particular interest, with NYHA I-II, spironolactone was not associated with reduced all-cause mortality. Our findings persisted after adjustment for propensity scores, in a cohort match based on propensity score and age, in sensitivity analyses accounting for missing data, and in subgroups NYHA I-II and NYHA III-IV. Eplerenone has been studied in NYHA II, but for spironolactone, our findings were novel for NYHA I-II and in contrast to RALES for NYHA III-IV.
Is RALES Applicable to a Contemporary Mild HF Population?
With large penetrance of the registry, the proportion receiving spironolactone, rather than eplerenone, was likely similar to that in Sweden overall, that is, >98%. In Sweden, costs are 0.11 US$ per day for 25 mg spironolactone and 3.20 US$ per day for 25 mg eplerenone (www.fass.se, accessed June 3, 2011). Therefore our findings may be considered applicable to spironolactone alone. Spironolactone is less specific than eplerenone for the mineralocorticoid receptor, and is associated with gynecomastia, impotence, and loss of libido, 16 and therefore lack of adherence. Spironolactone is associated with adverse metabolic effects 17 and anabolic deficiency, in turn associated with reduced survival, 18 and has active metabolites with long halflives, increasing the risk of hyperkalemia. 16 RALES did not include mild HF. In our study, half had NYHA I-II, and in the overall study and in the NYHA I-II subgroup, spironolactone was not associated with reduced mortality. These findings suggest that extrapolating RALES to milder HF should be done with caution.
RALES may also not be applicable to a contemporary HF population. Only 10% to 11% received β-blockers, compared with 89% to 91% in our population. β-Blockers and higher age are risk factors for renal insufficiency and hyperkalemia. 19 Modern therapy, including β-blockers, has also improved prognosis compared with the RALES era, perhaps, diluting the benefits of spironolactone and allowing adverse events to play a relatively larger role.
Is the Net Benefit Lower in the Community?
Although necessary to eliminate bias and confounding, RCTs may have limited generalizability. Patients are carefully selected. Elderly, women, minorities, and patients with comorbidities continue to be excluded. 6 Investigators may also avoid patients without formal exclusion criteria but anticipated to present more risk or complicated monitoring. Patients in RCTs are also more closely monitored, of particular importance because MRAs increase the risk of hyperkalemia and renal failure. 4,5,7,20-25 Potassium >5.0 mEq/L, or creatinine >220 µmol/L (2.5 mg/dL), or glomerular filtration rate <30 mL/min per 1.73 m 2 were exclusion criteria in the RCTs 1-3 and are contraindications in guidelines. 4, 5 A metaanalysis of 19 RCTs of MRAs, a majority spironolactone, suggested considerably increased risk of hyperkalemia and renal failure. 20 In broad unselected HF populations followed in the community, monitoring is less stringent and in Canada after the publication of RALES, prescription of spironolactone increased 5-fold, some of which may have been offlabel, hospitalization for hyperkalemia increased 4-fold, and associated mortality increased 7-fold. 7 Similar observations were made in the United States. 25 Other studies have demonstrated adverse events that have been more common and severe than expected based on the RCTs, especially in patients of older age, diabetes mellitus, with other comorbidities and when spironolactone are used in higher doses or in combination with a RAS-antagonist. 7, [20] [21] [22] [23] [24] When potassium rises to ≥5.5 mEq/L, mortality may increase as much as 2-to 10-fold. 26 Figure 2 . Hazard ratios (HR) for all-cause mortality for patients receiving vs not receiving spironolactone from the multivariable model adjusted for propensity scores, the listed variable, and the interaction between spironolactone and the listed variable. ACEI indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; EF, ejection fraction; MAP, mean arterial pressure; NYHA, New York Heart Association; and RAS, renin-angiotensin system.
One third use of spironolactone in our study was similar to MRA use in the US Get With the Guidelines Registry. 27 It was appropriately higher in EF <30% than in 30% to 39%, but it was equal in NYHA I-II compared with NYHA III-IV. This low use in appropriate patients (NYHA III-IV for spironolactone) has been seen in other studies, 25, 27 and given the potentially lower risk of adverse events in appropriate patients with adequate monitoring, 28 should perhaps be expanded. In contrast, one third is high in NYHA I-II, for whom spironolactone has not been studied. Indeed, spironolactone may be used inappropriately in the community, 29, 30 may be associated with benefit in specialized HF clinics, but not in the general community, 31, 32 and may be one of the most significant causes of drug-related harm in HF 21 .
Mean age in RALES was 65, compared with 71 in our study. Our patients also had worse renal function and with older age may have had more noncardiac comorbidities. These factors may not only increase the risks from spironolactone, but also may be associated with more noncardiac mortality, less likely to be prevented by spironolactone.
Our findings are also corroborated by 2 other registry analyses. In Registry to Improve Heart Failure Therapies in the Outpatient Setting (IMPROVE-HF), all evidence-based drug therapies in HF except MRAs were associated with incremental benefit. 33 The adjusted HR for mortality was 1.05 (95% CI, 0.74-1.51). In Comparative Effectiveness of Therapies for Heart Failure (COMPARE-HF), from the American Heart Association's Get With the Guidelines-HF Registry and Medicare claims data, the adjusted HR for mortality associated with MRAs was 1.04 (95% CI, 0.96-1.14). 8 Although the sample sizes were considerably lower and CIs considerably wider than ours, the point estimate for the HR was similar to ours: HR 1.05 (95% CI, 1.00-1.11). These 2 studies did not report type of MRA used nor interactions with or subgroup analyses by NYHA class. Thus, our study is the first to assess spironolactone in NYHA I-II. For renin-angiotensin system antagonists and β-blockers, RCTs and observational studies are highly consistent. 33 Indeed, in the same registry population as this study and with the same methodology, we recently showed that renin-angiotensin system antagonists are associated with an expected adjusted 20% reduction in mortality, 15 consistent with RCTs. 34 Thus, our registry is highly consistent with RCTs for reninangiotensin system antagonists, lending credibility to our registry and methodology, but inconsistent with RALES for spironolactone. This suggests that some HF therapies may be beneficial across wide populations and practice settings, whereas others, and potentially spironolactone, may be more sensitive to complex and variable risk/benefit profiles depending on clinical setting.
There were several statistically significant interactions. The HR was higher in NYHA I-II versus III-IV, providing a rationale for our subgroup analyses by NYHA class and lending support to our interpretation that spironolactone may not reduce mortality in mild HF. However, there were small differences between the NYHA I-II and III-IV subgroups, depending on type of analysis, and these should be interpreted with caution. Similarly, the HR was higher in EF 30% to 39% versus <30%. EF 30% to 39% may not be covered by RALES (EF ≤35%), again consistent with our interpretation. Paradoxically, in patients with age <73 years and creatinine clearance >50 mL/min, spironolactone was associated with higher risk. These interactions were statistically significant. The reasons are not readily apparent. It is possible that younger patients (such as NYHA I-II) had lower HF-associated risk and thus lower net benefit, that patients in our study with lower perceived risk were less closely monitored, or that patients with higher risk developed renal failure and were taken off spironolactone, in a sense crossed over in our intention-to-treat analysis. With testing for numerous interactions, some may become significant because of chance, and these analyses should be interpreted with caution.
Other Potential Explanations
Our patients differ from the RCTs in additional ways. RALES and EPHESUS reduced sudden cardiac death, and EPHESUS required an acute myocardial infarction in the last 3 to 14 days, suggesting an antiarrhythmic effect. Only 53% of our population had ischemic pathogenesis. Addition of an angiotensin receptor blocker to an angiotensin converting enzyme inhibitor reduces cardiovascular death and HF hospitalization, 35 but the combination of an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, and MRA is considered contraindicated because of risks of hyperkalemia and renal failure. 4, 5 Of patients receiving spironolactone, 3.5% also received both angiotensin converting enzyme inhibitor and angiotensin receptor blocker and may have been at increased risk. In EPHESUS, patients were acutely ill, and RALES and EMPHASIS-HF required a HF hospitalization in the past 6 months. Half of our patients were registered in outpatient clinics and a majority had duration of HF ≥6 months, suggesting that our patients may have been more stable or more chronic. Conversely, patients in the RCTs had survived a recent hospitalization and may have been subject to immortality bias, whereas our patients were registered even if the index hospitalization was associated with death.
Limitations
The nonrandomized design is subject to bias and confounding. 36 However, there were small differences in known variables between groups, and none remained after adjustment for propensity score. Importantly, we cannot rule out effects of potential unmeasured confounders. These include potentially more careful follow-up in patients receiving spironolactone, confounding in favor of spironolactone, or perceived more severe disease in patients receiving spironolactone (eg, factors other than those available in the registry and adjusted for in our study, that nonetheless increase the propensity for prescribing spironolactone), confounding against. The quantification of residual confounding reduces, but cannot compensate for, this major limitation.
In a registry study, treatment may change over time and adherence is not monitored, and our study reflects therapy with spironolactone at the time of inclusion. However, this is true also in intention-to-treat randomized studies. Furthermore, we do not have serial potassium or creatinine measurements nor causes of death. Although we hypothesize that adverse events may outweigh benefits in the community, we cannot show that this is the reason for the lack of net benefit of spironolactone in our study.
Although most hospitals and many primary care clinics in Sweden report to the registry, we do not have complete coverage throughout Sweden, and there may be biases associated with differences between centers that do and do not report to the registry. However, because RCTs generally are performed at academic medical centers, these are associated with even more selection bias.
There were missing data on some variables, most importantly potassium. Although we performed multiple imputation to reduce bias attributable to data not missing at random, and sensitivity analyses excluding both variables and patients with missing data, we cannot rule out remaining confounding attributable to missing data.
Conclusion
In conclusion, our findings suggest that spironolactone may not be associated with reduced all-cause mortality in a broad unselected contemporary population with HF and reduced EF, of particular interest in NYHA I-II. Because RALES indicated benefit of spironolactone in NYHA III-IV, our observations should be interpreted very cautiously in this patient group. We propose that MRAs should be used appropriately, based on the RCTs and guidelines. However, we raise the possibility that the net benefits of spironolactone may be lower outside the clinical trial setting and in milder HF.
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